Compare Baxter International Inc (BAX) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Innodata Inc — how do they compare? Baxter International Inc trades at $26.99 (market cap $14.27B), while Innodata Inc trades at $61.97 (market cap $2.05B). The key difference: Baxter International Inc is far larger — about 7× Innodata Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| BAX | INOD | |
|---|---|---|
Market Cap | $14.27B | $2.05B |
Sector | Health | Technology |
52-Week High | $28.35 | $121.50 |
52-Week Low | $15.80 | $34.45 |
Enterprise Value | $21.79B | $1.80B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
INOD trades at $61.40, down 1.33% today, but maintains a bullish technical signal with oscillators supporting upside momentum. The company reported strong Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and AI-driven demand expansion. Valuation ratios remain elevated with a P/E of 48.62, reflecting high growth expectations.
Outlook is positive given consistent earnings beats and AI sector tailwinds, but risks include premium valuation sensitivity and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
